Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00248209 | Female Orgasmic Disorder (FOD) and Wellbutrin XL | PHASE2 | COMPLETED | 48 | — | — | May 1, 2004 | Apr 1, 2007 | Jul 20, 2011 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Wellbutrin XL or placebo | PLACEBO_COMPARATOR | 1 arms - Wellbutrin XL or placebo |
| Name | Type | Description |
|---|---|---|
| Wellbutrin XL | DRUG | Patients randomized to the bupropion treatment group will receive bupropion XL150 mg in the AM for 7 days increasing to 300mg/day (single daily dose). The investigator can increase the dose to 450mg per day at Day 28 if clinically indicated. |
Inclusion Criteria: A subject must: 1. Be able to understand and sign a written informed consent 2. Be a premenopausal female between 20 and 50 years of age, inclusive 3. Use active birth control, and be non-lactating, with a negative urine pregnancy test 4. Have no evidence of mood or anxiety dis...